Benzimidazole AnthelminthicPopulation PK (1-CMT drug-metabolite, first-pass)OralInfectious Disease

Oxfendazole Population PK — Tablet Formulation in Healthy African Adults

Indication: Onchocerciasis (river blindness)

Interactive population PK simulator for oxfendazole tablet formulation. Drug-metabolite model with first-pass metabolism and dose-limited bioavailability for onchocerciasis dose optimization.

Drug Overview

Clinical Context

Molecular Target
Onchocerca volvulus (adult worms)
Drug Class
Benzimidazole Anthelminthic
Therapeutic Area
Infectious Disease
Indication
Onchocerciasis (river blindness)
Route of Administration
Oral

Model Information

Model Type
Population PK (1-CMT drug-metabolite, first-pass)

This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.

Pharmacokinetic Parameters

PK Parameters

ParameterValue
Ka0.695 1/h
CL F3.54 L/h

Additional Parameters

ParameterValue
doses100mg single, 400mg single, 400mg QD x 5 days
methodNONMEM FOCE-I
drug nameOxfendazole
V F67.2 L
f M0.5 -
f FP0.0549 -
V FEN F3370 L
V SO2 F206 L
CL FEN F94.4 L/h
CL SO2 F15.8 L/h

Parameters sourced from published population pharmacokinetic models. Values represent typical population estimates; individual patient parameters may vary.

About This Simulator

This interactive pharmacokinetic simulator for Oxfendazole Population allows you to explore concentration-time profiles under different dosing scenarios. The underlying Population PK (1-CMT drug-metabolite, first-pass) model characterizes the pharmacokinetics of this benzimidazole anthelminthic following oral administration.

Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).

Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.

Frequently Asked Questions

What is the Oxfendazole Population PK simulator?

This is a free, interactive pharmacokinetic simulator for Oxfendazole Population used in Onchocerciasis (river blindness). It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.

What drug class does Oxfendazole Population belong to?

Oxfendazole Population is classified as a Benzimidazole Anthelminthic that targets Onchocerca volvulus (adult worms). It is used in the Infectious Disease therapeutic area.

What route of administration does this model simulate?

This simulator models Oral administration of Oxfendazole Population. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.

What type of PK model is used?

This simulator uses a Population PK (1-CMT drug-metabolite, first-pass) model. This model characterizes the time-course of drug concentrations following dosing.

Is this simulator free to use?

Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.

Can I use this for clinical dosing decisions?

No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.

Related Simulators

Ready to Simulate?

Launch the Oxfendazole Population simulator to explore dosing scenarios and pharmacokinetic profiles interactively.

🚀 Launch Simulator

Comments

0/2000
Loading comments...

⚠️ Disclaimer

This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.

Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community